| pubmed-article:15458455 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15458455 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:15458455 | lifeskim:mentions | umls-concept:C0002986 | lld:lifeskim |
| pubmed-article:15458455 | lifeskim:mentions | umls-concept:C0475463 | lld:lifeskim |
| pubmed-article:15458455 | lifeskim:mentions | umls-concept:C0596530 | lld:lifeskim |
| pubmed-article:15458455 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:15458455 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15458455 | pubmed:dateCreated | 2004-10-1 | lld:pubmed |
| pubmed-article:15458455 | pubmed:abstractText | Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of alpha-Gal A antibodies in treated patients. | lld:pubmed |
| pubmed-article:15458455 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15458455 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15458455 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15458455 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15458455 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:15458455 | pubmed:author | pubmed-author:LinthorstGabo... | lld:pubmed |
| pubmed-article:15458455 | pubmed:author | pubmed-author:AertsJohannes... | lld:pubmed |
| pubmed-article:15458455 | pubmed:author | pubmed-author:HollakCarla... | lld:pubmed |
| pubmed-article:15458455 | pubmed:author | pubmed-author:StrijlandAnne... | lld:pubmed |
| pubmed-article:15458455 | pubmed:author | pubmed-author:Donker-Koopma... | lld:pubmed |
| pubmed-article:15458455 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15458455 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:15458455 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15458455 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15458455 | pubmed:pagination | 1589-95 | lld:pubmed |
| pubmed-article:15458455 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:meshHeading | pubmed-meshheading:15458455... | lld:pubmed |
| pubmed-article:15458455 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15458455 | pubmed:articleTitle | Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. | lld:pubmed |
| pubmed-article:15458455 | pubmed:affiliation | Department of Internal Medicine/Clinical Hematology, Academic Medical Center, Amsterdam, The Netherlands. G.E.Linthorst@amc.uva.nl | lld:pubmed |
| pubmed-article:15458455 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15458455 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15458455 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15458455 | lld:pubmed |
